Immunology Investor Event

Amlitelimab treatment decreases key Type 2 and non- Type 2 pathway biomarkers in AD¹ patients IL-13 IL-22 IL-17A Log10(IL-13:Fold change vs Baseline) (median ± 95%CI) 0.5- 0.0- -0.5- ns Baseline D113 D29 Placebo amlitelimab Phase 2a data ns **** *** Baseline D29 D113 Log10(IL-22:Fold change vs Baseline) (median ± 95%CI) 1.0- 0.5- 0.0- -0.5- -1.0- Baseline ns **** ns * | D29 D113 Baseline D29 D113 ns *** 0.2- ns ns 0.1- Log10(IL-17A:Fold change vs Baseline) (median ± 95%CI) 0.0- -0.1- -0.2- | Baseline D29 D113 Baseline D29 D113 ****p<0.0001; ***p<0.001; *p<0.05; Baseline vs Day 29/113 (Two-way ANOVA with Dunnett's multiple comparisons test). Amlitelimab is currently under clinical investigation, and its safety and efficacy have not been evaluated by any regulatory authority 32 Immunology Investor Event sanofi

View entire presentation